Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

January 14, 2020
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

January 10, 2020
Aptinyx Announces Pricing of Public Offering of Common Stock

January 9, 2020
Aptinyx Announces Proposed Public Offering of Common Stock

December 12, 2019
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

December 9, 2019
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting

See all press and news »